News on EluSys Therapeutics Incorporated from BioPortfolio.com http://www.BioPortfolio.com Consolidated EluSys Therapeutics Incorporated news from BioPortfolio.com Wed, 10 Feb 2010 07:25:57 GMT en FDA Tough on Cell Therapeutics' Drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030969&HITNO=0&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030969&THISHREF=http://c.moreover.com/click/here.pl%3fz2533919865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030969&HITNO=0&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030969&THISHREF=http://c.moreover.com/click/here.pl%3fz2533919865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTheStreet.com: FDA Tough on Cell Therapeutics' Cancer Drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030472&HITNO=1&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030472&THISHREF=http://c.moreover.com/click/here.pl%3fz2533646174%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030472&HITNO=1&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030472&THISHREF=http://c.moreover.com/click/here.pl%3fz2533646174%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTheStreet.com: Reportlinker Adds Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012576&HITNO=2&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012576&THISHREF=http://c.moreover.com/click/here.pl%3fz2523467433%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012576&HITNO=2&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012576&THISHREF=http://c.moreover.com/click/here.pl%3fz2523467433%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Finance: Reportlinker Adds Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012527&HITNO=3&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012527&THISHREF=http://c.moreover.com/click/here.pl%3fz2523455059%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012527&HITNO=3&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012527&THISHREF=http://c.moreover.com/click/here.pl%3fz2523455059%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Reportlinker Adds Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013117&HITNO=4&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013117&THISHREF=http://c.moreover.com/click/here.pl%3fz2523615678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013117&HITNO=4&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013117&THISHREF=http://c.moreover.com/click/here.pl%3fz2523615678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPhoenix Business Journal: Reportlinker Adds Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012525&HITNO=5&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012525&THISHREF=http://c.moreover.com/click/here.pl%3fz2523454846%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012525&HITNO=5&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012525&THISHREF=http://c.moreover.com/click/here.pl%3fz2523454846%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: BioMarin to Acquire LEAD Therapeuticshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017737&HITNO=6&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017737&THISHREF=http://c.moreover.com/click/here.pl%3fz2525275889%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017737&HITNO=6&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017737&THISHREF=http://c.moreover.com/click/here.pl%3fz2525275889%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTickerTech.com: Top Biotechnology Gainer Stocks were NASDAQ: CTIC, ACAD, CRXXhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017290&HITNO=7&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017290&THISHREF=http://c.moreover.com/click/here.pl%3fz2525070222%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017290&HITNO=7&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017290&THISHREF=http://c.moreover.com/click/here.pl%3fz2525070222%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Globe: Phase 2a clinical trial results of VX-809 in patients with CF announcedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4010492&HITNO=8&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4010492&THISHREF=http://c.moreover.com/click/here.pl%3fz2522490375%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4010492&HITNO=8&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4010492&THISHREF=http://c.moreover.com/click/here.pl%3fz2522490375%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Ribonucleic Acid (RNA) Therapeutics - Strong Potential To Address Unmet Needs In Pharma - New Market Report Puhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005377&HITNO=9&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005377&THISHREF=http://c.moreover.com/click/here.pl%3fz2520344895%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005377&HITNO=9&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005377&THISHREF=http://c.moreover.com/click/here.pl%3fz2520344895%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOfficialSpin: Ribonucleic Acid (RNA) Therapeutics - Strong Potential To Address Unmet Needs In Pharma - New Market Report Publishedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005337&HITNO=10&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005337&THISHREF=http://c.moreover.com/click/here.pl%3fz2520329072%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005337&HITNO=10&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005337&THISHREF=http://c.moreover.com/click/here.pl%3fz2520329072%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOfficialWire: Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystichttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4008660&HITNO=11&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4008660&THISHREF=http://c.moreover.com/click/here.pl%3fz2521620768%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4008660&HITNO=11&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4008660&THISHREF=http://c.moreover.com/click/here.pl%3fz2521620768%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006026&HITNO=12&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006026&THISHREF=http://c.moreover.com/click/here.pl%3fz2520567367%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006026&HITNO=12&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006026&THISHREF=http://c.moreover.com/click/here.pl%3fz2520567367%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystichttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005437&HITNO=13&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005437&THISHREF=http://c.moreover.com/click/here.pl%3fz2520360609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005437&HITNO=13&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005437&THISHREF=http://c.moreover.com/click/here.pl%3fz2520360609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Vertex Pharma (VRTX) Announces Positive VX-809 Phase 2ahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005346&HITNO=14&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005346&THISHREF=http://c.moreover.com/click/here.pl%3fz2520331275%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005346&HITNO=14&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=EluSys%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005346&THISHREF=http://c.moreover.com/click/here.pl%3fz2520331275%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: